

FORM PTO-1595 (modified)

(Rev 6-93)

07-18-2006



103276744

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

COVER SHEET

-Y

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

Peter D. DAVIS

2. Name and address of receiving party(ies):

Angiogene Pharmaceuticals Ltd.
Aston Rowant, Watlington
14 Plowden Park
Oxfordshire
OX9 5SW
Great Britain

113264 U.S. PTO
11/483639



071106

Additional conveying party(ies)

NO

3. Nature of conveyance:

ASSIGNMENT

Execution Date:

September 16, 2001

Additional name(s) & address(es) attached?

NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is:

September 16, 2001

A. Patent Application Number(s):

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Gilberto M. Villacorta, PH.D.
FOLEY & LARDNER LLP
Washington Harbour
3000 K Street NW, Suite 500
Washington, D.C. 20007-5143

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

Check Enclosed

☒

Authorized to be charged to credit card

Authorized to be charged to deposit account

8. Payment Information

a. Credit Card Last 4 Numbers 8688
Expiration Date 03/31/2009

b. Deposit account number 19-0741
Authorized User Name Gilberto M. Villacorta

DO NOT USE THIS SPACE

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Gilberto M. Villacorta, PH.D.

July 11, 2006

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 4

07/12/2006 ZJUHAR1 00000021 11483639

05 FC:8021

(40.00 DP)

For: ☐ U.S. and/or ☐ Foreign Rights
For: ☐ U.S. Application or
☐ U.S. Provisional Application
For: ☐ U.S. Patent
For: ☒ PCT Application
By: ☐ Inventor(s) or ☐ Present Owner

ASSIGNMENT OF INVENTION

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR:

Inventor(s) or person(s) or entity(ies)
who own the invention

Peter David DAVIS

(type or print name(s) of ASSIGNOR(S))

10 Aston Prk, Aston Rowant, Watlington.

Address

OX9 5SW, Great Britain

BRITISH

Nationality

*(if assignment is by person or entity to whom invention was previously assigned
and this was recorded in PTO, add the following)*

Recorded on _____ Reel _____
Frame _____

hereby sells, assigns and transfers to

ASSIGNEE:

ANGIOGENE PHARMACEUTICALS LTD.

(type or print name(s) of ASSIGNEE(S))

14 Plowden Park, Aston Rowant, Watlington.

Address

Oxfordshire, OX9 5SW, Great Britain

BRITISH

Nationality

and the successors, assigns and legal representatives of the ASSIGNEE.

(Assignment of Invention—page 1 of 3) 16-3

(complete one of the following)

☒ the entire right, title and interest

☐ an undivided _____ percent (_____ %) interest

for the United States and its territorial possessions

(check the following box, if foreign rights are also to be assigned)

☐ and in all foreign countries, including all rights to claim priority,

in and to any and all improvements which are disclosed in the invention entitled:

BENZIMIDAZOLE VASCULAR DAMAGING AGENTS

Name of inventor(s) Peter David DAVIS

(check and complete (a), (b), (c), (d), (e), (f) or (g))

and which is found in (37 C.F.R. § 3.21)

(a) ☐ U.S. patent application executed on even date herewith

(b) ☐ U.S. patent application executed on _____

(c) ☐ U.S. provisional application naming the above inventor(s) for the above-entitled invention.

☐ Express mail label no.: _____

Mailed: _____

☐ To comply with 37 CFR 3.21 for recordal of this assignment, I, an ASSIGNOR signing below, hereby authorize and request my attorney to insert below the filing date and application number when they become known.

(d) ☐ U.S. application no. _____ filed on _____

(e) ☒ International application no. PCT / GB00 / 00099 filed on 14 January 2000

(f) ☐ U.S. patent no. _____ issued _____

☐ A change of address to which correspondence is to be sent regarding patent maintenance fees is being sent separately.

(also check (g), if foreign application(s) is also being assigned)

(g) ☐ and any legal equivalent thereof in a foreign country, including the right to claim priority

and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

(Assignment of Invention—page 2 of 3) 16-3

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

WARNING: The date of signing must be the same as the date of execution of the application, if item (a) was checked above.

Date: (x) September 16th 2001

(x)

Signature of ASSIGNOR(S)

Date: _____

Date: _____

Date: _____

(If ASSIGNOR is a legal entity, complete the following information)

(type or print the name of the above person
authorized to sign on behalf of ASSIGNOR)

Title

NOTE: No witnessing, notarization or legalization is necessary. If the assignment is notarized or legalized, then it will only be prima facie evidence of execution. 35 USC 261. Use next page if notarization is desired.

[] Notarization or Legalization Page Added.

(Assignment of Invention—page 3 of 3) 16-3

For: ☐ U.S. and/or ☐ Foreign Rights
For: ☐ U.S. Application or
☐ U.S. Provisional Application
For: ☐ U.S. Patent
For: ☒ PCT Application
By: ☐ Inventor(s) or ☐ Present Owner

ASSIGNMENT OF INVENTION

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR:

Inventor(s) or person(s) or entity(ies)
who own the invention

Peter David DAVIS

(type or print name(s) of ASSIGNOR(S))

10 Aston Park, Aston Rowant, Watlington.

Address

OX9 5SW, Great Britain

BRITISH

Nationality

(if assignment is by person or entity to whom invention was previously assigned
and this was recorded in PTO, add the following)

Recorded on _____ Reel _____
Frame _____

hereby sells, assigns and transfers to

ASSIGNEE:

ANGIOGENE PHARMACEUTICALS LTD.

(type or print name(s) of ASSIGNEE(S))

14 Plowden Park, Aston Rowant, Watlington.

Address

Oxfordshire, OX9 5SW, Great Britain

BRITISH

Nationality

and the successors, assigns and legal representatives of the ASSIGNEE

(complete one of the following)

☒ the entire right, title and interest

☐ an undivided _____ percent (_____ %) interest

for the United States and its territorial possessions

(check the following box, if foreign rights are also to be assigned)

☐ and in all foreign countries, including all rights to claim priority,

in and to any and all improvements which are disclosed in the invention entitled:
BENZIMIDAZOLE VASCULAR DAMAGING AGENTS

Name of inventor(s) Peter David DAVIS

(check and complete (a), (b), (c), (d), (e), (f) or (g))

and which is found in (37 C.F.R. § 3.21)

- (a) ☐ U.S. patent application executed on even date herewith
(b) ☐ U.S. patent application executed on _____
(c) ☐ U.S. provisional application naming the above inventor(s) for the above-entitled invention.
☐ Express mail label no.: _____
Mailed: _____
☐ To comply with 37 CFR 3.21 for recordal of this assignment, I, an ASSIGNOR signing below, hereby authorize and request my attorney to insert below the filing date and application number when they become known.
(d) ☐ U.S. application no. _____ filed on _____
(e) ☒ International application no. PCT/GB00 / 00099 filed on 14 January 2000
(f) ☐ U.S. patent no. _____ issued _____
☐ A change of address to which correspondence is to be sent regarding patent maintenance fees is being sent separately.

(also check (g), if foreign application(s) is also being assigned)

(g) ☐ and any legal equivalent thereof in a foreign country, including the right to claim priority

and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

(Assignment of Invention—page 2 of 3) 16-3

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

WARNING: The date of signing must be the same as the date of execution of the application, if item (a) was checked above.

Date: (X) September 16th 2001

(X)

Signature of ASSIGNOR(S)

Date: _____

Date: _____

Date: _____

(if ASSIGNOR is a legal entity, complete the following information)

(type or print the name of the above person
authorized to sign on behalf of ASSIGNOR)

Title

NOTE: No witnessing, notarization or legalization is necessary. If the assignment is notarized or legalized, then it will only be prima facie evidence of execution. 35 USC 261. Use next page if notarization is desired.

[] Notarization or Legalization Page Added.

(Assignment of Invention—page 3 of 3) 16-3